Redd&Whyte Appoints New Director of Business Development
News Aug 23, 2012
The appointment is one of a series of new hires, amid strategic restructuring within Redd&Whyte.
Rob Harkness brings specialist technical understanding of software and robotics, in addition to an impressive track record in business development.
He joins Redd&Whyte from Process Analysis & Automation, Ltd (PAA), where he worked for 13 years, initially as a software programmer and project manager, before progressing to leading Business Development in 2010.
His PhD (University of Surrey) focused on novel scheduling software for biochemical assays.
Rob made a significant contribution to PAA’s success in becoming a major provider of laboratory automated solutions, and will now lead Redd&Whyte’s global Business Development team.
“This is a crucial time for our company,” said Roger Poole, Managing Director at Redd&Whyte. “We have been making significant changes on a number of levels over the past few months, and Rob’s appointment forms an important part of our new business strategy.”
“It also demonstrates our continued commitment to developing enabling technology for our customers, through our approach of open innovation,” Roger said.
Roger continued, “Our products, including the award-winning Preddator microplate dispenser, are all developed through close collaboration with our customers, to help solve their liquid handling challenges and overcome perceived barriers to research.”
Redd&Whyte is involved in developing a range of novel robotic instruments with the fluid handling capabilities that laboratory scientists need to actually achieve their research visions.
The company’s specialist areas include nano dispensing, high throughput screening and point of care (PoC) testing.
Tiny Kidneys: Building Better Models to Test DrugsNews
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.READ MORE
New Drug to Treat Herpes Simplex Virus Infection?News
Researchers have now identified a small drug molecule that can clear the HSV-1 infection in the cells of the cornea -- the clear outer layer of the eyeball -- and works completely differently than the currently-available drugs, making it a promising potential option for patients who have developed resistance.READ MORE
Radioprotective Drugs Assessed Using Human Gut Organ-on-a-ChipNews
Researchers have published a study using an organ-on-a-chip (Organ Chip) model of the human gut that reveals the intestinal blood vessel cells may play an important part in radiation-induced intestinal injury, and it confirms that a potential radioprotective drug, dimethyloxaloylglycine (DMOG), suppresses the intestine’s responses to radiation injury.READ MORE